Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VRXA
Strong SellVeraxa Biotech AG · Healthcare · Germany · $191M · Avg Vol: $295K/d
1
StockRankGet insider-trade alerts
Q
20
V
33
M
5
P/E (TTM)
—
ROE
-65.3%
D/E
—
Dividend %
—
COMPANY DESCRIPTION
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment.
FINANCIAL SUMMARY (USD)
| Year | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 23.4K | — | 23.4K |
| EPS | -0.12 | -0.20 | -0.47 | — | -0.59 |
| Shares | 141.4M | 141.4M | 141.4M | 0.0% | 141.4M |
| Debt | 0 | 0.9M | 2.1M | 147.6% | 2.1M |
| Equity | 55.1M | 31.1M | -15.8M | -43.7% | — |
| Op CF | -7.3M | -7.7M | -9.9M | — | -7.7M |
| Inv CF | -1.0M | -0.1M | -0.4M | — | — |
| Fin CF | 12.5M | 1.9M | 6.6M | — | — |
Loading 1Y...
PRICE (1Y)-36.3%
SMA 50SMA 200
Close
$1.35
RSI (14)
22.2
52W High
$27.36
From 52W High
0.0%
SCORE BREAKDOWN
Quality
20
ROIC
-90.3%7.9
ROE
-65.3%15.5
GP/Assets
0.0%11.0
Op. Margin
0.0%40.1
FCF/Assets
-12.8%27.8
Piotroski
322.6
Int. Cover
-50.0x6.2
D/E Ratio
—N/A
Current Ratio
2.20x42.5
Value
33
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
0.6x94.2
P/S
9899.6x0.8
Div Yield
—N/A
Momentum
5
52W High %
5%0.3
RS 6M
-100%0.2
SMA 50/200
0.23x0.3
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$191M
P/E (Forward)
—
Gross Margin
66.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VRXA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VRXA | Veraxa Biotech AG(you) | $191M | 1 | Strong Sell |
| FYB.DE | Formycon AG | $380M | 36 | Hold |
| IFRX | InflaRx N.V. | $329M | 39 | Hold |
| IMTX | Immatics N.V. | $1.4B | 11 | Strong Sell |
| BNTX | BioNTech SE | $25.6B | 28 | Sell |
| NNNN | Anbio Biotechnology | $337M | 19 | Strong Sell |
| QUCY | Quantum Cyber N.V. | $119M | 21 | Sell |
| EVT.DE | Evotec SE | $689M | 20 | Sell |
| ILM1.DE | Medios AG | $326M | 74 | Buy |
| LIK.DE | LIMES Schlosskliniken AG | $193M | 89 | Strong Buy |
Peer medians: ROE 7.2% · P/E 16.5x · Gross margin 45.1%